Traws Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
TRAW$0.24+8.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
Condensed Consolidated Statements of Operations (unaudited)
| | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Three Months Ended September 30, · · Nine Months Ended September 30, · | |||||||||||||
| · 2025 · 2024 · 2025 · 2024 | |||||||||||||
| Revenue | | $— | | $57,000 | | $2,790,000 | | $170,000 | | ||||
| Operating expenses: | | | | | | | | | | | | | |
| Acquired in-process research and development | | — | | — | | — | | 117,464,000 | | ||||
| Research and development | | 2,311,000 | | 5,113,000 | | 7,108,000 | | 10,989,000 | | ||||
| General and administrative | | 1,744,000 | | 3,480,000 | | 6,189,000 | | 8,813,000 | | ||||
| Total operating expenses | | 4,055,000 | | 8,593,000 | | 13,297,000 | | 137,266,000 | | ||||
| Loss from operations | | (4,055,000) | | (8,536,000) | | (10,507,000) | | (137,096,000) | | ||||
| Change in fair value of warrant liability | | | (3,000) | | | — | | | 26,656,000 | | | — | |
| Other income, net | | 96,000 | | 61,000 | | 464,000 | | 495,000 | | ||||
| Net (loss) income | | $(3,962,000) | | $(8,475,000) | | $16,613,000 | | $(136,601,000) | | ||||
| Net (loss) income attributable to common stockholders, basic and diluted | | $(3,035,000) | | $(1,433,000) | | $12,263,000 | | $(33,255,000) | | ||||
| Weighted-average shares of common stock outstanding, basic | | | 8,818,859 | | | 961,530 | | | 7,851,515 | | | 1,043,781 | |
| Net (loss) income per share of common stock, basic | | $(0.34) | | $(1.49) | | $1.56 | | $(31.86) | | ||||
| Weighted-average shares of common stock outstanding, diluted | | | 8,818,859 | | | 961,530 | | | 8,006,487 | | | 1,043,781 | |
| Net (loss) income per share of common stock, diluted | | $(0.34) | | $(1.49) | | $1.53 | | $(31.86) | | ||||
| Net (loss) income attributable to Series C Preferred stockholders, basic and diluted | | $(927,000) | | $(7,042,000) | | $4,350,000 | | $(103,346,000) | | ||||
| Weighted-average shares of Series C Preferred outstanding, basic and diluted | | | 6,737 | | | 11,816 | | | 6,962 | | | 8,109 | |
| Net (loss) income per share of Series C Preferred, basic and diluted | | $(137.60) | | $(595.97) | | $624.82 | | $(12,744.60) | | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.